Idexx Laboratories, Inc. · NASDAQ:IDXX
Idexx Laboratories — Q4 2023 Earnings Presentation
5 slides from Idexx Laboratories's earnings presentation, Feb 5, 2024
Slide 1: IDEXX Q4 & Full Year 2023 Earnings Highlights
IDEXX Q4 & Full Year 2023 Earnings Highlights (NASDAQ: IDXX) Operating Diluted Revenue Profit Earnings Per Share Q4 $902M $245M $2.32 Reported growth: +9% 27% of Revenue Organic growth: +8% Reported growth: +13% YoY change in basis points: CAG Diagnostics Recurring Reported -10 Comparable growth: +1
Slide 2: 2024 Growth and Financial Performance Outlook Commentary
IDEXX Q4 & Full Year 2023 Earnings Highlights (NASDAQ: IDXX) 2024 Growth and Financial Performance Outlook Commentary • Provides initial outlook for 2024 revenue of $3,930 million - $4,040 million, reflecting reported revenue growth of 7.5% - 10.5% and organic growth of 7% - 10%, driven by 7.5% - 10
Slide 3: U.S. Companion Animal Practice Growth Update
+ + + + + + + U.S. Companion Animal Practice Growth Update As of December 31, 2023 Total Practice Revenue and Visit Growth Weighted Average Year-over-Year % Change Per Practice* 20% 15% 13.6% Practice Revenue 9.0% 10% 7.0% 6.2% 4.7% 5.1% 4.5% 4.8% 4.3% 5% 5.0% 0% 2.1% Total Visits 0.5% 0.5% -0.8% -1
Slide 4: U.S. Companion Animal Practice Growth Update: Q4 2023 Contributors
+ + + + + + + U.S. Companion Animal Practice Growth Update As of December 31, 2023 Contributors to U.S. Companion Animal Diagnostic Revenue Growth per Practice** Q4’2023 + 7.5% + 7.0% Year-Over-Year Growth (%) - 0.5% + 0.0% + 9.0% + 7.0% Q4’2022 - 2.5% + 0.5% + 6.5% + 14.5% + 2.0% Q4 Average + 6.0%
Slide 5: U.S. Companion Animal Practice Growth Update: FY 2023 Contributors
+ + + + + + + U.S. Companion Animal Practice Growth Update As of December 31, 2023 Contributors to U.S. Companion Animal Diagnostic Revenue Growth per Practice** FY’2023 + 8.5% + 8.0% Year-Over-Year Growth (%) - 0.5% + 0.0% + 8.0% + 7.0% FY’2022 - 2.0% + 1.0% + 6.0% + 13.5% + 2.0% FY Average + 5.5%